Efficacy and Safety Study of HS-10542 for IgA Nephropathy

Summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.

Timeline

Start

2026-03-17

Primary completion

2027-12-10

Completion

2028-01-30

Drugs

Indications